Reedsburg man gets 5 months after pleas
******************************
wiscnews - (US) The officer met Newkirk at the park and questioned him about wanting to sell prescription drugs, records state. Newkirk must take alcohol and other drug abuse treatment, register as a sex offender and take other counseling and treatment his probation agent requires. (Wed Nov 18 20:34:46 2009 PST)
Opposing Views: NEWS:Should Medical Marijuana Be Used to Treat Kids With Autism?
******************************
opposingviews - (US) DEA Ignores AMA's New Medical Marijuana Policy Advocacy Group to Sue L.A. if Medical Marijuana Sales are Banned Life in Prison for Growing Marijuana? (Tue Nov 17 10:42:39 2009 PST)
Alkermes Initiates Phase 2 Clinical Study of ALKS 33 for the Treatment of ...
******************************
pharmalive - ALKS 33 is an oral opioid modulator that builds on Alkermes&rsquo. (Tue Nov 17 07:48:38 2009 PST) [also genengnews5092, earthtimes.org8309]
Leerink Swann Upgrades Alkermes (ALKS) to Outperform; Significant Market ...
******************************
streetinsider - StreetInsider.com - Leerink Swann Upgrades Alkermes (ALKS) to Outperform; Significant Market Opportunity in Opioid Dependence StreetInsider.com - Leerink Swann Upgrades Alkermes (ALKS) to Outperform; Significant Market Opportunity in Opioid Dependence Leerink Swann Upgrades Alkermes (ALKS) to Outperform; Significant Market Opportunity in Opioid Dependence Leerink Swann Upg... (Tue Nov 17 05:08:44 2009 PST)
Sam's Story: Medical Marijuana and Autism - KTLA
******************************
ktla - (US) The cannabis was a godsend for Sam's family. (Mon Nov 16 22:19:26 2009 PST)
Phase 3 study of lomitapide (AEGR-733) to lower LDL cholesterol
**************************
empr - Phase 3 study of extended-release injectable naltrexone for treatment of opioid dependence ... (Mon Nov 16 11:34:04 2009 PST)
Alkermes Announces Positive Results from Phase 3 Clinical Study of Naltrexone ...
******************************
pharmalive - Medical treatment for opioid dependence is an established and growing pharmaceutical market. Yet there are limitations with currently available therapies. Multi-center study was designed to assess the efficacy and safety of XR-NTX compared to placebo treatment in opioid dependent subjects who have been recently detoxified and abstinent from opioids for a minimum of seven days prior to treatment initiation. (Mon Nov 16 11:19:52 2009 PST)